Could a single infusion of supercharged immune cells tame incurable autoimmune diseases?

NCT ID NCT07038447

First seen Jan 06, 2026 · Last updated May 01, 2026 · Updated 19 times

Summary

This early-phase study is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathy that haven't improved with standard therapies. KITE-363 uses a patient's own immune cells, which are modified in a lab to target and destroy faulty immune cells causing the disease. The goal is to see if this approach is safe and can reduce disease activity, potentially allowing patients to stop or reduce other medications, though lifelong management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Concord Repatriation General Hospital

    Sydney, New South Wales, 2139, Australia

  • Jewish General Hospital

    Montreal, H3T1E2, Canada

  • St Vincent's Hospital

    Fitzroy, Victoria, 3065, Australia

  • Stanford University

    Stanford, California, 94305, United States

  • The Ottawa Hospital, General Campus

    Ottawa, K1H 8L6, Canada

Conditions

Explore the condition pages connected to this study.